Nachrichten zur Hofseth BioCare ASA Aktie

Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") holds 1,500,000 shares personally…

HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B…

Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a…

HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first…

Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of Hofseth BioCare ASA (“HBC”) to pursue…

Ålesund, Norway, 8 October 2024.…

HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half…

Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces…

Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an…

The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs…

The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the companys premises at Keiser Wilhelms…

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today…

Today, 5 April 2024, funds managed by Bonafide (Bonafide Global Fish Fund, Bonafide Best Catches I, HBC I, and HBC…